Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.
Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.
复制标题
小鼠乳腺癌 (16/C) 的生物学和治疗反应及其作为手术辅助化疗模型的潜力。
DOI：
--
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
F. Schabel
中科院分区：
文献类型：
--
作者：
T. Corbett;Griswold Dp;Roberts Bj;J. Peckham;F. Schabel
一个乳腺腺癌（16/C）被分离出来，并通过肺转移灶移植在连续传代中维持。该肿瘤起源于C3H/He雌性小鼠的自发性乳腺腺癌。我们从50多个乳腺肿瘤中选择了它作为模型因为它具有高度转移性而且它对大多数据说对女性乳腺癌有效的药物都有反应。Sc植入的16/C肿瘤（在300- 1000 mg范围内）转移到肺部的小鼠超过75%，转移到腋窝淋巴结的小鼠超过30%。这种肿瘤已被测试对超过40种临床使用的药物的敏感性。阿霉素是最具活性的单药。其他活性药物包括环磷酰胺、5-氟尿嘧啶、长春新碱、美伐兰、二溴调醇、美坦辛、新羧抑素、palmo - ala - c、长春花碱和VP-16-213。对40- 1000毫克肿瘤最有效的药物对微转移性疾病也最有效（如阿霉素）。反之亦然;对40- 1000毫克肿瘤无活性或微弱活性的药物对微转移性疾病（如BCNU）最多是微弱活性。超过20毫克的肿瘤不能通过单独化疗治愈，尽管阿霉素治疗在超过80%的小鼠中导致100- 400毫克肿瘤完全消退。手术切除300- 1000mg肿瘤加上阿霉素治疗的治愈率为40%- 72%，而仅手术治愈率为0- 26%。数据产生与其他药物治疗，单独和联合，提出。
A mammary adenocarcinoma (16/C) was isolated and maintained in serial passage by transplantation of metastatic lung foci. This tumor originated as a spontaneous mammary adenocarcinoma in a C3H/He female mouse. It was selected as a model from greater than 50 mammary tumors studied because it was highly metastatic and because it responded to most of the agents reported to be active against breast cancer in women. Sc implanted 16/C tumors (in the 300--1000-mg range) metastasized to the lungs in greater than 75% of the mice and to the axillary lymph nodes in greater than 30%. This tumor has been tested for sensitivity to greater than 40 clinically used agents. Adriamycin was the most active single agent. Other active agents included cyclophosphamide, 5-fluorouracil, vincristine, melphalan, dibromodulcitol, maytansine, neocarzinostatin, palmO-ara-C, vinblastine, and VP-16-213. Agents most active against 40--1000-mg tumours were also most active against micrometastatic disease (eg, adriamycin). The converse was also true; agents inactive or marginally active against 40--1000-mg tumors were at best marginally active against micrometastatic disease (eg, BCNU). Tumors greater than 20 mg were not curable by chemotherapy alone, although adriamycin treatment caused complete regressions of 100--400-mg tumors in greater than 80% of the mice. Surgical removal of 300--1000-mg tumors plus therapy with adriamycin resulted in 40%--72% cures as compared to 0--26% cures with surgery only. Data resulting from treatment with other agents, singly and in combination, are presented.